Upstream Manufacturing Webinars

  1. Behind The Data: Engineering Hepatocyte-Targeted LNPs 9/23/2026

    See how lipid nanoparticle platforms can deliver RNA and large DNA payloads to primary human T cells, improving transfection, expression durability, and CAR insertion efficiency.

  2. Behind The Data: Comprehensive Off-Target Assessment Strategies 9/23/2026

    Explore how biochemical, computational, and cell-based methods can identify, confirm, and interpret off-target editing risks, providing a more complete safety assessment for CRISPR-based therapeutics.

  3. Challenges And Opportunities For MSC Expansion Workflows 9/22/2026

    Discover how optimizing cell culture platforms and closed systems reduces manufacturing costs, improves media efficiency, and supports scalable stem cell production.

  4. Improving Scale-Up Starts With Expression Strategy 9/21/2026

    Early expression screening and strain-engineering strategies can reveal manufacturing risks and clarify which recombinant protein candidates are worth advancing before major investments are made.

  5. Why Use The GSquad® Pro Vector System? 9/18/2026

    Lonza's GSPro® vector platform centers on LHP1, a high-strength promoter developed to improve titer, product quality, and expression stability across a range of recombinant protein formats.

  6. How Does GS piggyBac® Transposon Technology Work? 9/18/2026

    Targeted genomic integration offers a more deliberate path to stable, high-expressing CHO cell lines than random integration methods have traditionally allowed.

  7. How Can The GS Effex® Cell Line Increase The Potency Of Therapeutic Antibodies? 9/18/2026

    Learn how GS Effex® integrates into our GS Gene Expression System®, letting customers use the same expression vectors, GS piggyBac® transposase technology, and media while incorporating the cell line into existing workflows.

  8. What Is The GS Discovery® Transient Expression System? 9/18/2026

    Two transient expression approaches, one optimized for speed and one for higher titers, are examined alongside the consistency advantages of a shared host cell and vector system.

  9. How Do I Choose An Expression System For My Biotherapeutic Molecule? 9/18/2026

    Selecting an expression system early in biotherapeutic development depends on molecular complexity, glycosylation requirements, and other structural characteristics that differ across platforms.

  10. Bylok® Platform For IgG-like Bispecific Antibody Assembly 9/18/2026

    Developing IgG-like bispecific antibodies poses significant expression and product-quality challenges. Discover how the bYlok® platform is designed to address these challenges and enable more efficient bispecific development.